Notice to Insurers of Potential Claim Controls
Post 4992
See the full video at https://rumble.com/v6j63k7-notice-to-insurers-of-potential-claim-controls.html and at https://youtu.be/OPsYVoOpevc
The Supreme Court of Delaware, En Banc, dealt with an insurance coverage dispute where Alexion Pharmaceuticals, Inc. appealed a decision from the Superior Court of Delaware.
In Re Alexion Pharmaceuticals, Inc. Insurance Appeals, Nos. 154, 2024, 157, 2024, Supreme Court of Delaware, en banc (February 4, 2025).
ISSUE
The issue before the Supreme Court was whether a Securities and Exchange Commission (SEC) investigation disclosed to Alexion’s insurers is related to a later securities class action brought against the company. The Superior Court found that the two were unrelated. The Supreme Court reversed this decision, finding that the securities class action arose out of the circumstances disclosed by Alexion to its first tower insurers.
FACTS
Alexion Pharmaceuticals, Inc. develops therapies for people living with rare disorders. Alexion was insured under two claims-made director and officer (“D&O”) liability insurance programs covering different periods. The first program provided $85 million of coverage for claims made between June 27, 2014 and June 27, 2015 (“Tower 1”). The second program provided $105 million of coverage for claims made between June 27, 2015 and June 27, 2017 (“Tower 2”). The two towers consist largely of the same insurers located in the same coverage layers. Both towers are structured as ABC directors and officers policies covering securities claims against the company. Each tower is composed of a primary policy and follow-form excess policies.
NOTICE REQUIRED BY POLICIES
The Insureds first became aware of facts or circumstances which may reasonably give rise to a future Claim covered under this Policy, and if the Insureds give written notice to the Insurer during the Policy Period a description of the anticipated Wrongful Act allegations.
Soliris is an “orphan drug” developed by Alexion that treats rare genetic diseases. In 2017, Soliris had about 11,000 customers worldwide. Soliris had a retail price of $500,000 to $700,000 for each patient. The SEC Investigation Order raised possible violations of the federal securities laws.
On June 18, 2015, Alexion sent its Tower 1 insurers a notice (“2015 Notice”) disclosing Alexion’s receipt of the SEC Subpoena. Alexion also stated that the SEC Subpoena “seeks information related to Alexion’s recalls of specific lots of Soliris and related securities disclosures.”
On July 2, 2020, Alexion settled with the SEC for about $21.5 million (“SEC Settlement”). On September 12, 2023, Alexion settled the Securities Class Action for $125 million (“Securities Class Action Settlement”) more than the available limits.
ANALYSIS
The Supreme Court agreed that “meaningful linkage” is the appropriate standard of comparison. Alexion’s 2015 Notice was not a claim. Chubb accepted Alexion’s 2015 Notice “as a notice of circumstance that may give rise to a claim.”
The Supreme Court concluded that the Securities Class Action was meaningfully linked to the wrongful acts disclosed in the 2015 Notice. Both involve the same alleged wrongdoing and the Securities Class Action alleged the same wrongdoing investigated by the SEC and disclosed by Alexion in the 2015 Notice.
Both SEC investigations involved the same Wrongful Act – Alexion’s grantmaking activities. A meaningful linkage exists between the Securities Class Action and the SEC investigation as disclosed by Alexion in its 2015 Notice. Under the policies of both towers, the Securities Class Action claim is deemed to have been first made at the time the 2015 Notice was received by Chubb – during the Tower 1 coverage period. Therefore, coverage is under Tower 1. Applying the Prior Notice Exclusion provision of Tower 2, no coverage is available under Tower 2. The judgment of the Superior Court was reversed.
Claims made policies require reports of potential claims. Alexion told its insurers about a potential claim under its Tower 1 and was entitled to coverage for the suit that followed. The prior notice exclusion eliminated coverage for tower 2. Parties, and judges, must read the policy wording before making a decision on coverage and since there was a “meaningful linkage” between the notice and the actual claim, coverage was available under Tower 1 and not Tower 2 as established by the Supreme Court.
(c) 2025 Barry Zalma & ClaimSchool, Inc.
Please tell your friends and colleagues about this blog and the videos and let them subscribe to the blog and the videos.
Subscribe to my substack at https://barryzalma.substack.com/subscribe
Go to X @bzalma; Go to Newsbreak.com https://www.newsbreak.com/@c/1653419?s=01; Go to Barry Zalma videos at Rumble.com at https://rumble.com/account/content?type=all; Go to Barry Zalma on YouTube- https://www.youtube.com/channel/UCysiZklEtxZsSF9DfC0Expg
Go to the Insurance Claims Library – https://lnkd.in/gwEYk
Like this:
Loading…
Related
About Barry Zalma
An insurance coverage and claims handling author, consultant and expert witness with more than 48 years of practical and court room experience.
